Skip to main content

Advertisement

Table 2 Grade 3–4 adverse events occurring in ≥3 % of the safety population

From: Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

Adverse events Safety population (n = 80)
Patient with ≥1 grade 3–4 adverse event 48 (60.0)
Neutropenia 16 (20.0)
Decreased neutrophil counta 11 (13.8)
Anemia 9 (11.3)
Pneumonia 7 (8.8)
Decreased white blood cell count 6 (7.5)
Leukopenia 5 (6.3)
Thrombocytopenia 5 (6.3)
Upper respiratory tract infection 5 (6.3)
Fatigue 4 (5.0)
Decreased platelet count 4 (5.0)
Hypocalcemia 3 (3.8)
Hypokalemia 3 (3.8)
  1. All values n (%)
  2. aDecreased neutrophil count refers to a fall in absolute neutrophil count since the last cycle, but not a low enough count to be considered neutropenia